Format

Send to:

Choose Destination
See comment in PubMed Commons below
Bull Acad Natl Med. 2012 Oct;196(7):1295-305; discussion 1305-6.

[Medical and economic aspects of rheumatoid arthritis].

[Article in French]

Author information

  • 1Université Paris 6-Pierre & Marie Curie-GRC-08-EEMOIS, Rhumatologie, AP-HP, Groupe hospitalier Pitié-Salpêtrière, Paris cedex 13. bruno.fautrel@psl.aphp.fr

Abstract

Rheumatoid arthritis (RA) is a chronic disabling disease that induces substantial costs in terms of healthcare resources (direct costs) and lost productivity (indirect costs). The main cost drivers used to be disability and hospitalization. Recently, however, the cost of new and expensive therapies has exceeded that of hospitalization. These effective treatments have lowered RA-related use of healthcare resources, especially totaljoint replacement, as well as sick leave. In contrast, they have not yet been shown to reduce the number of patients who become disabled, and their cost-effectiveness ratio thus tends to be unfavorable.

PMID:
23815015
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk